Monitor the company's market capitalization closely ahead of the December 28, 2026 MVLS compliance deadline. Any reverse stock split or equity raise announcement would signal an attempt to maintain listing, while failure to act could lead to delisting proceedings.
Price Chart
Executive Summary
CytoSorbents announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, closing that deficiency. However, the company remains out of compliance with the separate $35 million Market Value of Listed Securities (MVLS) requirement, with a December 28, 2026 deadline to regain compliance or face potential delisting. The press release also reiterated forward-looking statements about achieving operating cash flow breakeven in H2 2026 and advancing DrugSorb-ATR toward FDA approval, but no financial results were reported.
Key Facts
- Regained compliance with Nasdaq minimum bid price requirement ($1.00/share) as of September 22, 2026, after 10 consecutive trading sessions above $1.00.
- Remains out of compliance with Nasdaq's $35 million Market Value of Listed Securities (MVLS) requirement, with a compliance deadline of December 28, 2026.
- Company is evaluating potential actions to regain MVLS compliance, including increasing stockholders' equity to at least $2.5 million.
- No financial results or revenue/earnings data were provided in this filing.
- CEO stated goal of achieving operating cash flow breakeven in the second half of 2026.
Financial Impact
No financial figures reported. The primary financial risk is potential delisting if MVLS compliance is not regained by December 28, 2026.
Risk Factors
- Failure to regain compliance with the $35 million MVLS requirement by December 28, 2026 could result in Nasdaq delisting.
- No financial results or guidance were provided, leaving the company's operational trajectory uncertain.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-109814 |
| Document: tm2625982d1_ex99-1.htm | 0001104659-26-109814 |
| Document: 0001104659-26-109814-index-headers.html | 0001104659-26-109814 |
| Document: 0001104659-26-109814-index.html | 0001104659-26-109814 |
| Document: 0001104659-26-109814.txt | 0001104659-26-109814 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $4.91 $5.35 | ▲ +8.96% | ▲ +8.27% | $4.29 (−12.70%) |
Aug 6, 2026 11w ago | Press Release | $0.3600 $0.3501 | ▲ +2.75% | ▲ +2.35% | $4.29 (−1090.61%) |
Jun 25, 2026 17w ago | DEFA14A | $0.3620 $0.3600 | ▼ −0.55% | ▼ −1.94% | $4.29 (+1084.03%) |
Jun 16, 2026 19w ago | Insider Cluster | $0.5189 $0.3694 | ▼ −28.81% | ▼ −28.86% | $4.29 (+726.02%) |
Apr 15, 2026 27w ago | 10-K/A | $0.6100 $0.5710 | ▼ −6.39% | ▼ −12.21% | $4.29 (+602.66%) |
Apr 2, 2026 29w ago | 8-K | $0.5830 $0.6100 | ▼ −4.63% | ▲ +5.25% | $4.29 (−635.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers